Integration of early palliative care in cancer treatment: a meta-analysis of 39 randomized controlled trials on clinical outcomes and management optimization
In brief
Early palliative care boosts quality of life and reduces death risk by 16%
A meta-analysis of 39 randomized trials involving 8,400 cancer patients found that integrating palliative care within 12 weeks of diagnosis improves quality of life by a modest but consistent margin and is associated with a roughly 16% lower risk of death. The survival signal is exploratory and data from low- and middle-income settings remain limited, so broader applicability needs further study.
- Journal
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (Q1)
- Published
- 19 September 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Zhenyang Long, Yuqi Zhao
- PMID
- 42760414
- DOI
- 10.1007/s00520-026-11246-0
Why clinicians should know about it
- Picked for Rehabilitation (top studies of the week, 20 September 2026): Early palliative care improves QoL, OS
- Picked for Radiation Oncology (top studies of the week, 20 September 2026): High-quality evidence in a top journal
- Picked for Surgical Oncology (top studies of the week, 20 September 2026): Early palliative care improves QoL and may extend survival in
Abstract
OBJECTIVE: To compare the effects of early palliative care (EPC) and standard cancer care in terms of QoL, survival, depression, and symptom burden in patients with cancer. Early palliative care refers to palliative care starting ≤ 12 weeks since diagnosis or the beginning of first-line treatment, alongside the usual cancer care. METHODS: Randomized controlled trials (RCTs) conducted until March 2026 and comparing EPC and standard care among adult patients with cancer were found using the search engines PubMed, Web of Science, Cochrane Library, CNKI, and Wanfang. The primary outcomes included QoL and OS; the secondary outcomes included depression and symptom burden. Meta-analysis was carried out using random-effect models to calculate SMDs and HRs. Potential biases were assessed with Cochrane RoB 2 and Egger's test. RESULTS: We included 39 RCTs (8399 patients, 2002-2024). EPC improved QoL significantly (SMD = 0.30, 95% CI 0.25-0.35, p < 0.001; I2 = 15.4%). An exploratory OS benefit was seen (HR = 0.84, 95% CI 0.78-0.90, p < 0.001; I2 = 25.4%). Results were consistent across cancer types and regions, and most trials were of low risk of bias and from North America/Europe. CONCLUSION: EPC enhances QoL and may extend the survival of cancer patients. These findings support early integration of palliative care, but findings for OS and generalizability to low- and middle-income countries (LMICs) should be interpreted with caution.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.